Skip to content
value.today

Pathway Therapeutics, Inc.

Total raised
$16 M
2 rounds on record
Latest round
$8 M
May 2011
First round on record
Jul 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pathway Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2011$8 MNo. 2$2 to $10 million

Pathway Therapeutics, Inc.: Raise no. 2, May 2011

Investors in this round

4 investors had bought by the notice of Jun 7, 2011: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julie Cherrington · Executive Officer, Director
  • Hillary Lewis · Director
  • Joshua Funder · Director
  • Mark Harvey · Director
  • Will Charles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $2,249,998.08 receivable by the Comp. upon the exercise of Warrants to purchase 2,556,816 shares of the Company's Series A-1 Preferred Stock at an exercise price of $0.88, assuming no cashless exercise. Such Warrants have not yet been exercised.”

Signed by Julie Cherrington, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 7, 2011. Read the notice at the SEC.

equity, optionsSEC
Jul 2010$9 MNo. 1$2 to $10 million

Pathway Therapeutics, Inc.: Raise no. 1, Jul 2010

Investors in this round

6 investors had bought by the notice of Aug 10, 2010: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $11 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julie Cherrington · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Julie Cherrington, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 10, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pathway Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2011).

    SEC Form D · Jun 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2011

That is all the official record says: Pathway Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pathway Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pathway Therapeutics, Inc.
NameRoleNamed in
Julie CherringtonExecutive officerJun 2011
Hillary LewisDirectorJun 2011
Joshua FunderDirectorJun 2011
Julie CherringtonDirectorJun 2011
Mark HarveyDirectorJun 2011
Will CharlesDirectorJun 2011